198 completed, 67 terminated, 37 recruiting, 19 unknown. 354 Phase 3, 63 Phase 2.
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) GV1001 Placebo, GV1001 1.12mg - Moderate to Severe Alzheimer's Disease | Phase 3 | Not yet recruiting | Samsung Pharmaceutical Co., Ltd. | 750 | 2027-07-01 | 2026-06-10 |
| Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study Tricaprilin, Placebo - Alzheimer Disease | Phase 3 | Not yet recruiting | Cerecin | 535 | 2027-07-01 | 2026-10-30 |
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 1600 | 2026-11-30 | 2026-10-13 |
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Acoramidis (AG10) - Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Not yet recruiting | Eidos Therapeutics, a BridgeBio company | 250 | 2026-11-01 | 2026-08-11 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| An Open-label Long-term Safety Study of Buntanetap in Participants With AD buntanetap/posiphen - Alzheimer's Dementia (AD) | Phase 2 / Phase 3 | Not yet recruiting | Annovis Bio Inc. | 400 | 2026-09-21 | 2026-08-19 |
| Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. [18F]-APN-1607 - Alzheimer's Disease | Phase 3 | Recruiting | JYAMS PET Research & Development Limited | 12 | 2026-08-15 | 2026-08-17 |
| Alzheimer's Disease THErapy With NEuroaid II MLC 901, Placebo - Alzheimer's Disease Dementia | Phase 3 | Not yet recruiting | Moleac Pte Ltd. | 350 | 2026-08-01 | 2026-06-12 |
| A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease Donanemab, RG6289, Donanemab placebo - Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease | Phase 2 / Phase 3 | Recruiting | Banner Health | 240 | 2026-07-08 | 2026-09-02 |
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 300 | 2026-06-03 | 2026-10-15 |
| Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain tributyrin, Placebo - Alzheimer Disease (AD) | Phase 3 | Not yet recruiting | Universidad de Almeria | 156 | 2026-06-01 | 2025-12-18 |
| Masitinib in Patients With Mild Alzheimer's Disease Placebo, Masitinib (4.5), Standard of care - Alzheimer Disease | Phase 3 | Not yet recruiting | AB Science | 600 | 2026-06-01 | 2025-10-03 |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). Donanemab, Placebo - Alzheimer Disease, Dementia | Phase 3 | Recruiting | Eli Lilly and Company | 550 | 2026-05-22 | 2026-10-28 |
| Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease Donanemab, Placebo - Alzheimer Disease | Phase 3 | Recruiting | Eli Lilly and Company | 140 | 2026-04-30 | 2026-08-24 |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo - Alzheimer Disease, Psychosis | Phase 3 | Recruiting | Bristol-Myers Squibb | 325 | 2026-03-25 | 2026-06-30 |
| Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function [18F]-APN-1607 - Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | Phase 3 | Recruiting | JYAMS PET Research & Development Limited | 316 | 2026-01-22 | 2026-02-20 |
| LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS) | Phase 3 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2025-12-22 | 2026-01-12 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-10-16 |
| Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia DMB-I (INN: Latrepirdine), Memantine Hydrochloride 20 MG, Placebo - Alzheimer Type Dementia | Phase 3 | Recruiting | Bigespas LTD | 450 | 2025-11-20 | 2025-12-10 |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimers Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1060 | 2025-11-12 | 2026-09-25 |
Showing 20 of 354. Sign in to see all of them.
Alzheimer Disease (346) · Dementia (104) · Cognitive Dysfunction (44) · Psychomotor Agitation (26) · Brain Diseases (18) · Memory Disorders (17) · Mental Disorders (16) · Neurodegenerative Diseases (16) · Nervous System Diseases (15) · Central Nervous System Diseases (11) · Amyloid Neuropathies, Familial (10) · Amyloidosis (9) · Dementia, Vascular (9) · Supranuclear Palsy, Progressive (9)
Central Nervous System Diseases (343) · Neurocognitive Disorders (340) · Nervous System Diseases (339) · Neurodegenerative Diseases (338) · Brain Diseases (336) · Mental Disorders (331) · Dementia (243) · Pathological Conditions, Signs and Symptoms (83) · Neurologic Manifestations (70) · Signs and Symptoms (68) · Neurobehavioral Manifestations (55) · Cognition Disorders (43) · Behavior (35) · Behavioral Symptoms (29)
Galantamine (19) · Donepezil (16) · Memantine (11) · gantenerumab (10) · Rivastigmine (8) · donanemab (8) · flutemetamol (8) · latrepirdine (8) · bapineuzumab (7) · solanezumab (7) · florbetapir (6) · Risperidone (5) · aducanumab (5) · lecanemab (5) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (4)
Eli Lilly and Company (19) · Hoffmann-La Roche (14) · Pfizer (14) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (13) · Otsuka Pharmaceutical Development & Commercialization, Inc. (12) · National Institute on Aging (NIA) (9) · Avid Radiopharmaceuticals (8) · Novartis Pharmaceuticals (8) · GE Healthcare (7) · Washington University School of Medicine (7) · Bristol-Myers Squibb (6) · H. Lundbeck A/S (6) · Axsome Therapeutics, Inc. (5) · Eidos Therapeutics, a BridgeBio company (5) · AstraZeneca (4)
United States (223) · Canada (112) · United Kingdom (94) · Spain (90) · France (89) · Germany (86) · Australia (80) · Italy (73) · South Korea (61) · Poland (60) · Japan (59) · Netherlands (48) · Argentina (44) · Belgium (41) · Sweden (39)
Randall J Bateman, MD (5) · James Kupiec, MD (3)
PMID 39498781, PMID 40603145, PMID 39800465, PMID 26120369, PMID 26402769, PMID 33189083, PMID 40681915, PMID 41533472, PMID 41961243, PMID 29318278, PMID 30474567, PMID 31193334, PMID 36946603, PMID 39108660, PMID 39556389, PMID 41537338, PMID 41591746, PMID 42552749, PMID 42841310, PMID 20921879, PMID 22749065, PMID 24450890, PMID 24450891, PMID 25125457, PMID 26208959, PMID 26297092, PMID 27176461, PMID 27334799, PMID 27494299, PMID 27767991, PMID 27807285, PMID 28269765, PMID 29615123, PMID 29854934, PMID 29854935, PMID 30412493, PMID 30558645, PMID 31353964, PMID 31708380, PMID 31764959, PMID 31831056, PMID 32107748, PMID 32524297, PMID 33049114, PMID 33070419, PMID 33587110, PMID 34807243, PMID 34923848, PMID 35384522, PMID 36121669
2016 (8), 2015 (7), 2025 (6), 2017 (5), U01AG010483 (5), U01AG059798 (5), 2023 (4), R01AG046179 (4), U01AG042791 (4), 2018 (3), R01AG053267 (3), R56AG053267 (3), 1RC2AG036535 (2), 2009 (2), 2019 (2)